Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | CA3 | P07451 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.48 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379733 | 0.98 | ACHE (0.50) | ACHECA1CA2CA12CA9 | |
| SCHEMBL2148897 | 0.92 | CA2 (0.53) | ACHECA1CA2CA12CA9 | |
| SCHEMBL21533037 | 0.87 | DDIT3 (0.43) | ACHECA1CA2CA12CA9 | |
| SCHEMBL1870250 | 0.84 | ADRB1 (0.46) | ACHECA1CA2CA12CA9 | |
| SCHEMBL2632975 | 0.84 | DDIT3 (0.53) | ACHECA1CA2CA12CA9 | |
| SCHEMBL12280404 | 0.84 | DDIT3 (0.44) | ACHEDDIT3TXNRD1GSRMMP1 | |
| Hydrochloric Acid SCHEMBL30005551 | 0.83 | ADRB1 (0.45) | ACHECA1CA2CA12CA9 | |
| SCHEMBL10799341 | 0.82 | APLNR (0.44) | ACHECA1CA2CA12CA9 | |
| SCHEMBL17373706 | 0.82 | SIRT6 (0.51) | ACHECA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL10795736 | 0.81 | ACHE (0.43) | ACHECA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381317-A1 | COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF | MODERN MEADOW INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4531795-A2 | COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF | HTL Biotechnology Innovation, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119562802-A | Collagen compositions and methods of use thereof | HTL生物创新股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-117897058-A | Collagen compositions and methods of use thereof | 现代牧场股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240099955-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | HTL BIOTECHNOLOGY INNOVATION INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4329521-A2 | COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF | Modern Meadow, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4288084-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | Modern Meadow, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023235775-A2 | COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF | MODERN MEADOW, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-116847871-A | Skin care compositions and methods of use | 现代牧场股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022232566-A2 | COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF | MODERN MEADOW, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| EP-1633748-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ACHE 32/4885CA1 4500/4885CA2 1594/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ACHE 32/4885CA1 4500/4885CA2 1594/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ACHE 32/4885CA1 4500/4885CA2 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.